SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Philip Thierry)
 

Search: WFRF:(Philip Thierry) > (2020-2024) > IL-2-mediated hepat...

IL-2-mediated hepatotoxicity : knowledge gap identification based on the irAOP concept

Roser, Luise A. (author)
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Sakellariou, Christina (author)
Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
Lindstedt, Malin (author)
Lund University,Lunds universitet,Institutionen för immunteknologi,Institutioner vid LTH,Lunds Tekniska Högskola,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH,LUCC: Lund University Cancer Centre,Other Strong Research Environments
show more...
Neuhaus, Vanessa (author)
Fraunhofer Institute for Toxicology and Experimental Medicine
Dehmel, Susann (author)
Fraunhofer Institute for Toxicology and Experimental Medicine
Sommer, Charline (author)
Fraunhofer Institute for Toxicology and Experimental Medicine
Raasch, Martin (author)
Dynamic42 GmbH
Flandre, Thierry (author)
Novartis Institutes of Biomedical Research, Switzerland
Roesener, Sigrid (author)
Merck Healthcare KGaA
Hewitt, Philip (author)
Merck Healthcare KGaA
Parnham, Michael J. (author)
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Sewald, Katherina (author)
Fraunhofer Institute for Toxicology and Experimental Medicine
Schiffmann, Susanne (author)
EpiEndo Pharmaceuticals ehf.
show less...
 (creator_code:org_t)
2024
2024
English.
In: Journal of Immunotoxicology. - 1547-691X. ; 21:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Drug-induced hepatotoxicity constitutes a major reason for non-approval and post-marketing withdrawal of pharmaceuticals. In many cases, preclinical models lack predictive capacity for hepatic damage in humans. A vital concern is the integration of immune system effects in preclinical safety assessment. The immune-related Adverse Outcome Pathway (irAOP) approach, which is applied within the Immune Safety Avatar (imSAVAR) consortium, presents a novel method to understand and predict immune-mediated adverse events elicited by pharmaceuticals and thus targets this issue. It aims to dissect the molecular mechanisms involved and identify key players in drug-induced side effects. As irAOPs are still in their infancy, there is a need for a model irAOP to validate the suitability of this tool. For this purpose, we developed a hepatotoxicity-based model irAOP for recombinant human IL-2 (aldesleukin). Besides producing durable therapeutic responses against renal cell carcinoma and metastatic melanoma, the boosted immune activation upon IL-2 treatment elicits liver damage. The availability of extensive data regarding IL-2 allows both the generation of a comprehensive putative irAOP and to validate the predictability of the irAOP with clinical data. Moreover, IL-2, as one of the first cancer immunotherapeutics on the market, is a blueprint for various biological and novel treatment regimens that are under investigation today. This review provides a guideline for further irAOP-directed research in immune-mediated hepatotoxicity.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)

Keyword

adverse event
Adverse outcome pathway
drug-induced liver injury
hepatotoxicity
immune safety
immunotherapy
interleukin-2
preclinical model

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view